Bridgeway Capital Management’s Regenxbio RGNX Stock Holding History

Bridgeway Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-198,630	Closed	-$3.76M	–	1437
2023 Q1	$3.76M	Buy	198,630 +28,730	+17%	+$636K	0.1%	338
2022 Q4	$3.85M	Hold	169,900	–	–	0.1%	338
2022 Q3	$4.49M	Buy	169,900 +25,000	+17%	+$742K	0.12%	303
2022 Q2	$3.58M	Buy	+144,900	New	+$3.62M	0.08%	380
2017 Q3	–	Sell	-27,852	Closed	-$550K	–	1435
2017 Q2	$550K	Hold	27,852	–	–	0.01%	1054
2017 Q1	$538K	Hold	27,852	–	–	0.01%	1049
2016 Q4	$517K	Sell	27,852 -37,000	-57%	-$707K	0.01%	1078
2016 Q3	$909K	Buy	+64,852	New	+$716K	0.01%	839

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Bridgeway Capital Management's RGNX Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Regenxbio (RGNX) in Q2 2023, closing a stake of 198,630 shares — an estimated $3.76M sold.

Bridgeway Capital Management first reported a position in RGNX in Q3 2016 and held it in 8 quarters. The position peaked at $4.49M in Q3 2022. 166 funds tracked by Wall St. Rank hold RGNX as of Q2 2023.

Bridgeway Capital Management reported no remaining Regenxbio position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 198,630 Regenxbio shares in Q2 2023, an estimated $3.76M.
Bridgeway Capital Management first reported a position in Regenxbio in Q3 2016 and held it in 8 quarters.
Bridgeway Capital Management's Regenxbio position peaked at $4.49M in Q3 2022.
166 funds tracked by Wall St. Rank held Regenxbio as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.